US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO
Allogene Therapeutics
Allogene Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
2017 Founded
208 Employees
Public company Type
ALLO · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2017
- Employees
- 208
- Programs
- 8
- Drugs
- 2
- Patents
- 16
Allogene Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Allogene Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Allogene Therapeutics in public FDA and regional records.